Haoyang Bio completed nearly 250 million yuan in Series B financing

Haoyang Bio is a technical service company specializing in the research and development of antibody and recombinant protein drugs. Haoyang Bio has the druggability analysis of antibody drugs, transient protein expression, antibody recombinant protein CMC development (stable cell line development, fermentation process development, purification process development, protein analysis method development and pilot production), antibody conjugated drugs (ADCs) development and other technology platforms. Recently, Haoyang Bio completed the B round of financing, with a transaction amount of nearly 250 million yuan. This round of financing was led by Shanghai Biomedical Fund, followed by Dongfang Jiafu, Haitong Kaiyuan, Xinghua Dingli, old shareholders Haibang Investment and Ginkgo Valley, and Shanna Capital acted as the exclusive financial advisor. The proceeds of this round of financing will be mainly used to improve the personnel team, build a 2000L production line, and solve the CMC difficulties of exosomes, mRNA and AAV.

This article is reproduced from: https://www.itjuzi.com/investevent/13488698
This site is for inclusion only, and the copyright belongs to the original author.

Leave a Comment